EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
AstraZeneca Settles Covid-Shot Suit With Christian Salesman
AstraZeneca PLC (AZN) Shares Gap Down to $62 on Apr 9
AstraZeneca (AZN) Faces Challenges Amid Potential Tariffs
RHHBY, LLY, AZN Face Market Pressure Due to New Tariff Concerns
AstraZeneca (AZN): A Long-Term Growth Opportunity Under $70
Fmr LLC Sells 805,930 Shares of AstraZeneca PLC (NASDAQ:AZN)
Peapack Gladstone Financial Corp Sells 47,590 Shares of AstraZeneca PLC (NASDAQ:AZN)
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca
AstraZeneca's Camizestrant Shows Promise in SERENA-6 Breast Cancer Trial
AstraZeneca (AZN) Gains EU Nod for Imfinzi Combo in NSCLC Treatment
AstraZeneca (AZN) Gains EU Approval for Expanded Enhertu Use in Breast Cancer
AstraZeneca (AZN) Gains Momentum with EU Drug Approvals
AstraZeneca (AZN) Prepares for Upcoming Earnings Amid Stock Decline
Solrikitug Emerges as a Promising Anti-TSLP Therapy for Severe Asthma, Poised to Address Critical Unmet Needs | DelveInsight | ABNewswire
Modified pegRNAs mitigate scaffold-derived prime editing by-products
Autologous T cell therapy for PRAME + advanced solid tumors in HLA-A*02 + patients: a phase 1 trial
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients
AstraZeneca PLC (AZN) Stock Price Down 5.81% on Apr 7
Arete Wealth Advisors LLC Grows Holdings in AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Buy" from Brokerages
China, America and pay inject drama into AstraZeneca's AGM
Pitcairn Co. Cuts Stake in AstraZeneca PLC (NASDAQ:AZN)
Just opened a Stocks and Shares ISA? Here are 10 stocks to consider buying, according to AI
AstraZeneca (NASDAQ:AZN) Shares Gap Up - What's Next?
Cinctive Capital Management LP Grows Stock Position in AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca (LON:AZN) Stock Price Passes Above 200-Day Moving Average - Time to Sell?
AstraZeneca PLC (AZN) Shares Down 6.67% on Apr 4
Daiichi Sankyo (4568) and AstraZeneca Receive EU Approval for Enhertu in Breast Cancer Treatment
Case: Patents/Antitrust (D. Del.)
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Nomura Asset Management Co. Ltd.
AstraZeneca And Daiichi Sankyo's Enhertu Approved In EU For Advanced Breast Cancer Treatment
Policy Fallout Continues; Rise in Lung Cancer Screening; Going Public With Denials
Precision Omics Initiative Sweden (PROMISE) will integrate research with healthcare
AstraZeneca PLC (LON:AZN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call Transcript
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
AstraZeneca CEO: China already a global innovation hub | govt.chinadaily.com.cn
AstraZeneca and Scientific Societies Unite for Multidisciplinary Care in Cardio-Renal-Metabolic Diseases
O Shaughnessy Asset Management LLC Cuts Stake in AstraZeneca PLC (NASDAQ:AZN)
Systems epigenetic approach towards non-invasive breast cancer detection
AstraZeneca CEO: China already a global innovation hub - Chinadaily.com.cn
Earnouts in M&A Transactions: Recent Decisions From Delaware
OncoHelix and AstraZeneca Partner to Provide Access to Liquid Biopsy Testing for Men with Prostate Cancer
HighPoint Advisor Group LLC Sells 188 Shares of AstraZeneca PLC (NASDAQ:AZN)
Franklin Resources Inc. Buys 357,894 Shares of AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca backs AI to accelerate lung cancer screening, shares evidence on impact in resource-limited settings, ET HealthWorld
FDA clears AstraZeneca's blockbuster Imfinzi for muscle-invasive bladder cancer treatment
Wellington Management Group LLP Lowers Holdings in AstraZeneca PLC (NASDAQ:AZN)
Clearbridge Investments LLC Lowers Position in AstraZeneca PLC (NASDAQ:AZN)
Summit Securities Group LLC Trims Stock Position in AstraZeneca PLC (NASDAQ:AZN)
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
AstraZeneca PLC (OTCMKTS:AZNCF) Sees Large Drop in Short Interest
AstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA Approval | Morningstar
LuNGS Alliance to enhance access to tailored cancer therapies in India | Health News - Business Standard
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Cancer Vaccines Market Growth Projections 2024-2034: DelveInsight Analysis | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma | ABNewswire
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study
Astrazeneca Plc (AZN) - Insider Monkey
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Orion Portfolio Solutions LLC
Modern Wealth Management LLC Buys Shares of 3,444 AstraZeneca PLC (NASDAQ:AZN)
Thrivent Financial for Lutherans Lowers Position in AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca PLC (NASDAQ:AZN) Stock Position Decreased by Accent Capital Management LLC
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
Berenberg Bank Reaffirms "Buy" Rating for AstraZeneca (LON:AZN)
Frontline Fulzerasib Plus Cetuximab Elicits Deep, Durable Responses in KRAS G12C-Mutated NSCLC
Howe & Rusling Inc. Grows Position in AstraZeneca PLC (NASDAQ:AZN)
FDA Approves Imfinzi (durvalumab) for Muscle Invasive Bladder Cancer
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | The Manila Times
Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC
41,404 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Penobscot Investment Management Company Inc.
Zions Bancorporation N.A. Raises Position in AstraZeneca PLC (NASDAQ:AZN)
J&J cancer combo reports better survival rate over AstraZeneca best-seller Tagrisso
BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment
Expanding access to dialysis coverage in Mexico
J&J Passes AstraZeneca in Lung Cancer Drug Race - For Now (1)
AstraZeneca's Win in Shareholder Suit Over Viela Sale Affirmed
Bạch Mai Hospital and AstraZeneca work together to improve patient care quality
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca | The Manila Times
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca | Morningstar
AstraZeneca's TAGRISSO Shows Promising Results in Lung Cancer Trials
Oxidation of retromer complex controls mitochondrial translation
"Absci" Tag - The Columbian
Virtu Financial LLC Reduces Holdings in AstraZeneca PLC (NASDAQ:AZN)
Quantbot Technologies LP Has $1.30 Million Position in AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca Seeks to Move Past China Probe With R&D Hub (1)
AstraZeneca puts faith in innovation - Chinadaily.com.cn
Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies | ABNewswire
In a $2B deal, Novo licenses obesity drug from China's United Bio | BioWorld
After China probe, is AstraZeneca's new US$2.5 billion plan a blueprint for foreign firms? | South China Morning Post
Guardian Partners Inc. Buys Shares of 47,564 AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca PLC (NASDAQ:AZN) Shares Bought by TD Private Client Wealth LLC
Prediction: 12 months from now, AstraZeneca's share price could be…
Pickleball Fights Severe Asthma For AstraZeneca's Fasenra 03/24/2025
Latest news
Stock market today: Most Asian stocks fell after US equities declined
MicroStrategy joins Nasdaq-100 index: MSTR stock performance analysis 2024
Morning Note: Tesla Soars, AUDUSD Hits Key Support, Oil & SP500 Insights
Nikkei 225 up 1.39%: Japanese Stocks Rise Following Yen's Continued Weakness
